EntryPoint Capital LLC Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

EntryPoint Capital LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 31,968 shares of the company’s stock, valued at approximately $353,000.

A number of other hedge funds also recently added to or reduced their stakes in STOK. Bank of New York Mellon Corp increased its position in Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after purchasing an additional 1,330 shares during the period. Rhumbline Advisers increased its holdings in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after buying an additional 2,787 shares during the period. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics in the fourth quarter worth approximately $63,000. Teacher Retirement System of Texas purchased a new stake in Stoke Therapeutics during the fourth quarter worth $113,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Stoke Therapeutics during the 4th quarter valued at $124,000.

Analyst Ratings Changes

STOK has been the topic of several analyst reports. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $24.67.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 over the last three months. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Stock Down 4.4 %

STOK stock opened at $7.40 on Thursday. The firm has a 50 day moving average of $9.40 and a 200 day moving average of $11.27. The stock has a market capitalization of $400.18 million, a PE ratio of -3.52 and a beta of 0.99. Stoke Therapeutics, Inc. has a 52 week low of $7.18 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.